Emerson Electric Co. has announced a significant financial move by entering into a pricing agreement for a public offering of €750 million in notes due 2032. This offering is expected to bolster the company’s financial position and support various corporate purposes.
The pricing agreement, dated November 10, 2026, involves major underwriters including J.P. Morgan Securities plc, Citigroup Global Markets Limited, Merrill Lynch International, and Goldman Sachs & Co. LLC. The notes will be sold at an issue price of 99.264% of their principal amount, with an expected closing date of November 13, 2026.
Background
Emerson Electric Co., incorporated in Missouri, is a prominent player in the electronic and other electrical equipment sector (SIC: 3600). The company trades on the New York Stock Exchange under the ticker symbol EMR. With a fiscal year ending on September 30, Emerson has consistently focused on innovation and efficiency in its operations.
What the Filing Says
The filing states, "The Notes are being sold to the Underwriters at an issue price of 99.264% of the principal amount thereof, and the Underwriters offered the Notes to the public at a price of 99.639% of the principal amount thereof." This highlights the competitive pricing strategy employed by Emerson to attract investors.
Impact
This offering may impact various stakeholders, including investors looking for fixed-income opportunities and competitors in the electronic and electrical equipment industry who may feel pressure to pursue similar financing options. The net proceeds from the sale are expected to be approximately €744.5 million, which Emerson plans to use primarily to repay commercial paper borrowings and for general corporate purposes.
What's Next
The notes are expected to be issued on November 13, 2026, and will be listed on the New York Stock Exchange. The filing does not specify any further actions required from shareholders or additional filings.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










